Therapeutic Effect of Curcumin on Metabolic Diseases: Evidence from Clinical Studies
- PMID: 36834734
- PMCID: PMC9959718
- DOI: 10.3390/ijms24043323
Therapeutic Effect of Curcumin on Metabolic Diseases: Evidence from Clinical Studies
Abstract
Metabolic diseases have become a serious threat to human health worldwide. It is crucial to look for effective drugs from natural products to treat metabolic diseases. Curcumin, a natural polyphenolic compound, is mainly obtained from the rhizomes of the genus Curcuma. In recent years, clinical trials using curcumin for the treatment of metabolic diseases have been increasing. In this review, we provide a timely and comprehensive summary of the clinical progress of curcumin in the treatment of three metabolic diseases, namely type 2 diabetes mellitus (T2DM), obesity and non-alcoholic fatty liver disease (NAFLD). The therapeutic effects and underlying mechanisms of curcumin on these three diseases are presented categorically. Accumulating clinical evidence demonstrates that curcumin has good therapeutic potential and a low number of side effects for the three metabolic diseases. It can lower blood glucose and lipid levels, improve insulin resistance and reduce inflammation and oxidative stress. Overall, curcumin may be an effective drug for the treatment of T2DM, obesity and NAFLD. However, more high-quality clinical trials are still required in the future to verify its efficacy and determine its molecular mechanisms and targets.
Keywords: clinical evidence; curcumin; diabetes; non-alcoholic fatty liver disease; obesity.
Conflict of interest statement
Authors declare no conflict of interest.
Figures




Similar articles
-
Phytochemicals for the treatment of metabolic diseases: Evidence from clinical studies.Biomed Pharmacother. 2023 Sep;165:115274. doi: 10.1016/j.biopha.2023.115274. Epub 2023 Aug 3. Biomed Pharmacother. 2023. PMID: 37542856 Review.
-
Is There a Role for Curcumin Supplementation in the Treatment of Non-Alcoholic Fatty Liver Disease? The Data Suggest Yes.Curr Pharm Des. 2017;23(7):969-982. doi: 10.2174/1381612822666161010115235. Curr Pharm Des. 2017. PMID: 27748192 Review.
-
Kaempferol efficacy in metabolic diseases: Molecular mechanisms of action in diabetes mellitus, obesity, non-alcoholic fatty liver disease, steatohepatitis, and atherosclerosis.Biomed Pharmacother. 2024 Jun;175:116694. doi: 10.1016/j.biopha.2024.116694. Epub 2024 May 6. Biomed Pharmacother. 2024. PMID: 38713943 Review.
-
Curcumin supplementation improves biomarkers of oxidative stress and inflammation in conditions of obesity, type 2 diabetes and NAFLD: updating the status of clinical evidence.Food Funct. 2021 Dec 13;12(24):12235-12249. doi: 10.1039/d1fo02696h. Food Funct. 2021. PMID: 34847213
-
Managing metabolic diseases: The roles and therapeutic prospects of herb-derived polysaccharides.Biomed Pharmacother. 2023 May;161:114538. doi: 10.1016/j.biopha.2023.114538. Epub 2023 Mar 15. Biomed Pharmacother. 2023. PMID: 36931026 Review.
Cited by
-
Dietary Approaches from Moms, Farms, and Nature to Overcome Chronic Diseases and the Pharmacracy.Nutrients. 2023 Sep 14;15(18):3965. doi: 10.3390/nu15183965. Nutrients. 2023. PMID: 37764749 Free PMC article.
-
Dendrimers as Nanocarriers for the Delivery of Drugs Obtained from Natural Products.Polymers (Basel). 2023 May 12;15(10):2292. doi: 10.3390/polym15102292. Polymers (Basel). 2023. PMID: 37242865 Free PMC article. Review.
-
Synthetic Curcumin Analogs in the Treatment of Cancer: A Literature Review.Curr Med Chem. 2025;32(17):3366-3388. doi: 10.2174/0109298673256932231123151626. Curr Med Chem. 2025. PMID: 38265396 Review.
-
Research Progress Regarding the Effect and Mechanism of Dietary Polyphenols in Liver Fibrosis.Molecules. 2023 Dec 25;29(1):127. doi: 10.3390/molecules29010127. Molecules. 2023. PMID: 38202710 Free PMC article. Review.
-
Potential mechanism of inhibitory effect of "medicine food homology" curcumin and its analogue EF24 on oral squamous cell carcinoma.Clin Transl Oncol. 2025 May 2. doi: 10.1007/s12094-025-03871-8. Online ahead of print. Clin Transl Oncol. 2025. PMID: 40314923
References
-
- Sun H., Saeedi P., Karuranga S., Pinkepank M., Ogurtsova K., Duncan B.B., Stein C., Basit A., Chan J.C.N., Mbanya J.C., et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 2022;183:109119. doi: 10.1016/j.diabres.2021.109119. - DOI - PMC - PubMed
-
- Williamson R.M., Price J.F., Glancy S., Perry E., Nee L.D., Hayes P.C., Frier B.M., Van Look L.A., Johnston G.I., Reynolds R.M., et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: The Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011;34:1139–1144. doi: 10.2337/dc10-2229. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical